Dimensional Fund Advisors LP Has $186.66 Million Holdings in United Therapeutics Co. (NASDAQ:UTHR)

Dimensional Fund Advisors LP increased its position in shares of United Therapeutics Co. (NASDAQ:UTHR) by 4.0% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 585,969 shares of the biotechnology company’s stock after acquiring an additional 22,683 shares during the quarter. Dimensional Fund Advisors LP owned 1.32% of United Therapeutics worth $186,656,000 as of its most recent SEC filing.

A number of other large investors have also made changes to their positions in the company. Plato Investment Management Ltd increased its stake in United Therapeutics by 7.1% in the 2nd quarter. Plato Investment Management Ltd now owns 4,008 shares of the biotechnology company’s stock valued at $1,277,000 after buying an additional 264 shares during the period. Envestnet Asset Management Inc. increased its stake in United Therapeutics by 12.7% in the 2nd quarter. Envestnet Asset Management Inc. now owns 48,981 shares of the biotechnology company’s stock valued at $15,603,000 after buying an additional 5,531 shares during the period. Oppenheimer Asset Management Inc. increased its stake in United Therapeutics by 2.2% in the 2nd quarter. Oppenheimer Asset Management Inc. now owns 25,852 shares of the biotechnology company’s stock valued at $8,235,000 after buying an additional 547 shares during the period. Parallel Advisors LLC increased its stake in United Therapeutics by 18.2% in the 2nd quarter. Parallel Advisors LLC now owns 937 shares of the biotechnology company’s stock valued at $298,000 after buying an additional 144 shares during the period. Finally, Dai ichi Life Insurance Company Ltd increased its stake in United Therapeutics by 10.5% in the 2nd quarter. Dai ichi Life Insurance Company Ltd now owns 9,202 shares of the biotechnology company’s stock valued at $2,931,000 after buying an additional 873 shares during the period. Institutional investors and hedge funds own 94.08% of the company’s stock.

United Therapeutics Stock Performance

NASDAQ:UTHR opened at $351.33 on Friday. United Therapeutics Co. has a 1 year low of $208.62 and a 1 year high of $366.08. The firm’s fifty day simple moving average is $338.00 and its 200 day simple moving average is $289.96. The company has a current ratio of 4.35, a quick ratio of 4.18 and a debt-to-equity ratio of 0.02. The firm has a market capitalization of $15.63 billion, a PE ratio of 16.58, a PEG ratio of 1.25 and a beta of 0.57.

United Therapeutics (NASDAQ:UTHR) last posted its earnings results on Wednesday, July 31st. The biotechnology company reported $5.85 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $6.33 by ($0.48). United Therapeutics had a net margin of 40.87% and a return on equity of 18.82%. The firm had revenue of $714.90 million during the quarter, compared to analyst estimates of $691.87 million. During the same quarter in the previous year, the business posted $5.24 earnings per share. The business’s quarterly revenue was up 19.8% compared to the same quarter last year. On average, sell-side analysts anticipate that United Therapeutics Co. will post 24.86 EPS for the current year.

Wall Street Analyst Weigh In

Several research firms have weighed in on UTHR. LADENBURG THALM/SH SH lowered shares of United Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Thursday, August 1st. Oppenheimer boosted their target price on shares of United Therapeutics from $400.00 to $575.00 and gave the stock an “outperform” rating in a research report on Wednesday, August 28th. Bank of America decreased their target price on shares of United Therapeutics from $303.00 to $280.00 and set an “underperform” rating for the company in a research report on Thursday, August 1st. StockNews.com downgraded shares of United Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Friday, August 2nd. Finally, HC Wainwright reissued a “buy” rating and issued a $400.00 target price on shares of United Therapeutics in a research report on Thursday, August 1st. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and ten have issued a buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $350.36.

Insiders Place Their Bets

In other United Therapeutics news, Director Raymond Dwek sold 5,000 shares of the firm’s stock in a transaction on Friday, August 2nd. The shares were sold at an average price of $325.35, for a total value of $1,626,750.00. Following the sale, the director now directly owns 1,750 shares in the company, valued at approximately $569,362.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In other United Therapeutics news, CEO Martine A. Rothblatt sold 3,600 shares of the firm’s stock in a transaction on Monday, June 24th. The shares were sold at an average price of $315.97, for a total value of $1,137,492.00. Following the sale, the chief executive officer now directly owns 130 shares in the company, valued at approximately $41,076.10. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Raymond Dwek sold 5,000 shares of the firm’s stock in a transaction on Friday, August 2nd. The stock was sold at an average price of $325.35, for a total transaction of $1,626,750.00. Following the completion of the sale, the director now owns 1,750 shares in the company, valued at $569,362.50. The disclosure for this sale can be found here. Insiders have sold 110,922 shares of company stock worth $36,541,398 in the last ninety days. Insiders own 12.50% of the company’s stock.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.